Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

This study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in elderly patients (aged 55-75) with acute myeloid leukemia (AML) who are fit for intensive chemotherapy.

Trial Details

NCT ID

NCT07132684

Phase

PHASE3

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Status

RECRUITING

Cancer Type

Leukemia

Interventions

Daunorubicin/Idarubicin
Cytarabine
Azacitidine
Venetoclax

Locations (sample)

Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

Diagnosis of AML according to WHO (2022) or ICC criteria.
Age ≥55 and ≤75 years.
ECOG performance status score of 0-2.
Adequate organ function:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →